Pages, Columns, Lines

where Relevant Passages or Relevant

Figures Appear

PTO/SSI084 (08-03.)
Approved for use through 07/31/2006, OMB 0661-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

> Application Number Filing Date

INFORMATION DISCLOSURE

10500929

2004-07-06

STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)			First Named Inventor Je		Jeffre	Jeffrey C. Felt		
			Art Unit			3733		
( NOT FOR SUBMISSION UNDER 37 CFR 1.99)				Examiner Na	Examiner Name Mich		nael J. Araj	
			Attorney Doo	Attorney Docket Number		32355.12.6.1.6		
				U.S.	PATENTS			
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5344459		1994-09-06	Bonutti			
	2	5549663		1996-06-27	Bonutti			
	3	6655165		2005-02-15	Fell et al.			
If you wis	h to a	dd additional U.S. Pater	t citatio	n information p	lease click	the A	dd button.	
			U.S.P	ATENT APPLI	CATION P	UBLK	CATIONS	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of of cited D		itee or Applicant ent	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1							
If you wis	h to a	dd additional U.S. Publis	shed Ap	plication citatio	n informati	ion ple	ease click the Ad	d button.

FOREIGN PATENT DOCUMENTS

Kind Publication

Code4 Date

Country

Code<sup>2</sup> i

Name of Patentee or

Applicant of cited

Document

1

Initial\* No Number<sup>3</sup>

Examiner Cite Foreign Document

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10500929		
Filing Date		2004-07-08		
First Named Inventor	Jeffre	y C. Felt		
Art Unit		3733		
Examiner Name	Micha	sel J. Araj		
Attorney Docket Number		32355.12.6.1.6		

If you wish to add additional Foreign Patent Document citation information please click the Add button

ĺ	NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials*			T5			
	1					

If you wish to add additional non-patent literature document citation information please click the Add button

# EXAMINER SIGNATURE

Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Plater Documents at sew\_USPTO\_GOV or MPEP 801.04. \* Enter office their issued the document, by the loc-intercode (WPD Standard ST3.). \* For Algenases petant comments, the indication of the parent of the sey for the Empore many precede the serial remover of the parent periods. \* Algenates petant periods see indicated on the cocument under VMPO Standard ST.16 if possible, \* Applicant is to place a check mark here if Empirils insquages treation in attached.

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10500929	
Filing Date		2004-07-08	
First Named Inventor Jeffrey C. Felt			
Art Unit		3733	
Examiner Name	Michael J. Araj		
Attaces Coales Numb	or	22255 12 6 1 6	

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication of from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a engine patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than these months prior to the filling of the information disclosure statement. Sec 37 CFR 137(c)(a).

See attached certification statement

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

X None

SIGNATURE

A signature of the applicant of prepresentative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature Date (YYY-MM-DD) 3007 01 39

Name/Print Philip M. degishan Registration Number 31162

This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is not lie (and by the USPTO to process) an application. Confidentially is governed by 35 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burders, should be sent to the Chief Information Officer, U.S. Palent and Trademark Office, U.S. Operatment of Commence, P. 0. Biol 1450, Alexandria, V.A. 2313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-78) requires that you be given certain information in connection with your submission of the attached form related to a patient policitation or patient. Accordingly, pursuants to the requirements of the Act, places be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familiarity of the information solicited is coultrain; and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademark Chiffice is to process and/or examine your submission related to a patient splicitation or patient. If you do not furnish the requested process and/or examine your submission related to a patient splicitation or patient. If you do not furnish the requested requirement of the patient of the patient of the patient of the patient authorisms, which may result in formination of or occederation or abandomment of the association or excitation of the patient.

The information provided by you in this form will be subject to the following routine uses:

to the Patent Cooperation Treaty.

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to Internation whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the
  - requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

    5. A record related to an International Application filter under the Patient Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an insepection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 152(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, guide, to the limitation of 37 CFR.11.4, as a routine use, but the public if the arcord was filled in application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.